Related Experiment Videos
Structure-based design of a dimeric zinc finger protein
J L Pomerantz1, S A Wolfe, C O Pabo
1Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge 02139, USA.
Biochemistry
|February 19, 1998
Summary
Researchers designed a novel dimeric zinc finger protein (ZFGD1) for targeted DNA binding. This engineered protein demonstrates high specificity and offers a versatile platform for gene therapy and biological research applications.
Area of Science:
- Molecular Biology
- Protein Engineering
- Genomics
Background:
- Designing novel DNA-binding proteins is crucial for advancing biological research and gene therapy.
- Zinc finger proteins (ZFPs) are key components in targeted DNA recognition.
- Existing ZFPs often require modifications for enhanced specificity and broader applications.
Purpose of the Study:
- To design and characterize a novel dimeric zinc finger protein, ZFGD1, with high DNA-binding specificity.
- To explore the potential of engineered ZFPs for gene targeting and therapeutic applications.
- To establish a prototype for designed DNA-binding proteins utilizing dimerization domains.
Main Methods:
- Computer modeling was employed to design the dimeric zinc finger protein ZFGD1.
- ZFGD1 incorporates zinc fingers 1 and 2 from Zif268 and a portion of the GAL4 dimerization domain.
- Phage display was used to select variants for altering DNA-binding specificity.
Main Results:
- ZFGD1 exhibits high-affinity and specific binding to its predicted DNA target site.
- The protein's DNA-binding specificity is primarily governed by its zinc finger domains.
- Systematic alteration of specificity is achievable through zinc finger substitution.
Conclusions:
- Engineered dimeric zinc finger proteins like ZFGD1 offer a powerful tool for precise genomic targeting.
- The fusion protein serves as a prototype for adaptable DNA-binding proteins with potential in gene therapy.
- The Cys2His2 zinc finger motif's adaptability, combined with dimerization, allows targeting of virtually any genomic site.